Jens D Lundgren1, Birgit Grund2, Christina E Barkauskas3, Thomas L Holland4, Robert L Gottlieb5, Uriel Sandkovsky5, Samuel M Brown6, Kirk U Knowlton7, Wesley H Self8, D Clark Files9, Mamta K Jain10, Thomas Benfield11, Michael E Bowdish12, Bradley G Leshnower13, Jason V Baker14, Jens-Ulrik Jensen15, Edward M Gardner16, Adit A Ginde17, Estelle S Harris18, Isik S Johansen19, Norman Markowitz20, Michael A Matthay21, Lars Østergaard22, Christina C Chang23, Anna L Goodman24, Weizhong Chang25, Robin L Dewar26, Norman P Gerry27, Elizabeth S Higgs28, Helene Highbarger29, Daniel D Murray30, Thomas A Murray2, Ven Natarajan31, Roger Paredes32, Mahesh K B Parmar33, Andrew N Phillips34, Cavan Reilly2, Adam W Rupert35, Shweta Sharma2, Kathryn Shaw-Saliba28, Brad T Sherman25, Marc Teitelbaum26, Deborah Wentworth2, Huyen Cao36, Paul Klekotka37, Abdel G Babiker38, Victoria J Davey39, Annetine C Gelijns40, Virginia L Kan41, Mark N Polizzotto42, B Taylor Thompson43, H Clifford Lane28, James D Neaton2. 1. CHIP Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark. 2. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota. 3. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University, Durham, North Carolina. 4. Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina. 5. Baylor University Medical Center, Dallas, Texas. 6. Intermountain Medical Center, Murray, and University of Utah, Salt Lake City, Utah. 7. Intermountain Healthcare, Salt Lake City, Utah. 8. Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 9. Section on Pulmonary, Critical Care, Allergy, and Immunology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina. 10. University of Texas Southwestern Medical Center, Dallas, Texas. 11. Department of Infectious Diseases, Hvidovre and Amager Hospital, University of Copenhagen, Hvidovre, Denmark. 12. Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California. 13. Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia. 14. Hennepin Healthcare Research Institute and University of Minnesota, Minneapolis, Minnesota. 15. CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, and Respiratory Medicine Section, Department of Internal Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 16. Denver Public Health, Denver Health and Hospital Authority, Denver, Colorado. 17. Department of Emergency Medicine, School of Medicine, University of Colorado, Aurora, Colorado. 18. University of Utah, Salt Lake City, Utah. 19. Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. 20. Department of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan. 21. Department of Medicine and Department of Anesthesia and Cardiovascular Research Institute, The University of California, San Francisco, San Francisco, California. 22. Aarhus University Hospital Skejby, Aarhus, Denmark. 23. The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. 24. Medical Research Council Clinical Trials Unit at University College London and Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom. 25. Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, Maryland. 26. Leidos Biomedical Research, Frederick, Maryland. 27. Advanced Biomedical Laboratories, Cinnaminson, New Jersey. 28. National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. 29. Leidos Biomedical Research and AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland. 30. CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark. 31. Laboratory of Molecular Cell Biology, Frederick National Laboratory for Cancer Research, Frederick, Maryland. 32. Infectious Diseases Department and IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 33. Medical Research Council Clinical Trials Unit and Institute of Clinical Trials and Methodology at University College London, London, United Kingdom. 34. Institute for Global Health, University College London, London, United Kingdom. 35. AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland. 36. Gilead Sciences, Foster City, California. 37. Eli Lilly and Company, Indianapolis, Indiana. 38. Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom. 39. U.S. Department of Veterans Affairs, Washington, DC. 40. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York. 41. Veterans Affairs Medical Center and School of Medicine and Health Sciences, George Washington University, Washington, DC. 42. The Kirby Institute, University of New South Wales, and St Vincent's Hospital, Sydney, New South Wales, Australia. 43. Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment. OBJECTIVE: To evaluate the a priori hypothesis that bamlanivimab has greater benefit in patients without detectable levels of endogenous neutralizing antibody (nAb) at study entry than in those with antibodies, especially if viral levels are high. DESIGN: Randomized, placebo-controlled trial. (ClinicalTrials.gov: NCT04501978). SETTING: Multicenter trial. PATIENTS: Hospitalized patients with COVID-19 without end-organ failure. INTERVENTION: Bamlanivimab (7000 mg) or placebo. MEASUREMENTS: Antibody, antigen, and viral RNA levels were centrally measured on stored specimens collected at baseline. Patients were followed for 90 days for sustained recovery (defined as discharge to home and remaining home for 14 consecutive days) and a composite safety outcome (death, serious adverse events, organ failure, or serious infections). RESULTS: Among 314 participants (163 receiving bamlanivimab and 151 placebo), the median time to sustained recovery was 19 days and did not differ between the bamlanivimab and placebo groups (subhazard ratio [sHR], 0.99 [95% CI, 0.79 to 1.22]; sHR > 1 favors bamlanivimab). At entry, 50% evidenced production of anti-spike nAbs; 50% had SARS-CoV-2 nucleocapsid plasma antigen levels of at least 1000 ng/L. Among those without and with nAbs at study entry, the sHRs were 1.24 (CI, 0.90 to 1.70) and 0.74 (CI, 0.54 to 1.00), respectively (nominal P for interaction = 0.018). The sHR (bamlanivimab vs. placebo) was also more than 1 for those with plasma antigen or nasal viral RNA levels above median level at entry and was greatest for those without antibodies and with elevated levels of antigen (sHR, 1.48 [CI, 0.99 to 2.23]) or viral RNA (sHR, 1.89 [CI, 1.23 to 2.91]). Hazard ratios for the composite safety outcome (<1 favors bamlanivimab) also differed by serostatus at entry: 0.67 (CI, 0.37 to 1.20) for those without and 1.79 (CI, 0.92 to 3.48) for those with nAbs. LIMITATION: Subgroup analysis of a trial prematurely stopped because of futility; small sample size; multiple subgroups analyzed. CONCLUSION: Efficacy and safety of bamlanivimab may differ depending on whether an endogenous nAb response has been mounted. The limited sample size of the study does not allow firm conclusions based on these findings, and further independent trials are required that assess other types of passive immune therapies in the same patient setting. PRIMARY FUNDING SOURCE: U.S. government Operation Warp Speed and National Institute of Allergy and Infectious Diseases.
BACKGROUND: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment. OBJECTIVE: To evaluate the a priori hypothesis that bamlanivimab has greater benefit in patients without detectable levels of endogenous neutralizing antibody (nAb) at study entry than in those with antibodies, especially if viral levels are high. DESIGN: Randomized, placebo-controlled trial. (ClinicalTrials.gov: NCT04501978). SETTING: Multicenter trial. PATIENTS: Hospitalized patients with COVID-19 without end-organ failure. INTERVENTION: Bamlanivimab (7000 mg) or placebo. MEASUREMENTS: Antibody, antigen, and viral RNA levels were centrally measured on stored specimens collected at baseline. Patients were followed for 90 days for sustained recovery (defined as discharge to home and remaining home for 14 consecutive days) and a composite safety outcome (death, serious adverse events, organ failure, or serious infections). RESULTS: Among 314 participants (163 receiving bamlanivimab and 151 placebo), the median time to sustained recovery was 19 days and did not differ between the bamlanivimab and placebo groups (subhazard ratio [sHR], 0.99 [95% CI, 0.79 to 1.22]; sHR > 1 favors bamlanivimab). At entry, 50% evidenced production of anti-spike nAbs; 50% had SARS-CoV-2 nucleocapsid plasma antigen levels of at least 1000 ng/L. Among those without and with nAbs at study entry, the sHRs were 1.24 (CI, 0.90 to 1.70) and 0.74 (CI, 0.54 to 1.00), respectively (nominal P for interaction = 0.018). The sHR (bamlanivimab vs. placebo) was also more than 1 for those with plasma antigen or nasal viral RNA levels above median level at entry and was greatest for those without antibodies and with elevated levels of antigen (sHR, 1.48 [CI, 0.99 to 2.23]) or viral RNA (sHR, 1.89 [CI, 1.23 to 2.91]). Hazard ratios for the composite safety outcome (<1 favors bamlanivimab) also differed by serostatus at entry: 0.67 (CI, 0.37 to 1.20) for those without and 1.79 (CI, 0.92 to 3.48) for those with nAbs. LIMITATION: Subgroup analysis of a trial prematurely stopped because of futility; small sample size; multiple subgroups analyzed. CONCLUSION: Efficacy and safety of bamlanivimab may differ depending on whether an endogenous nAb response has been mounted. The limited sample size of the study does not allow firm conclusions based on these findings, and further independent trials are required that assess other types of passive immune therapies in the same patient setting. PRIMARY FUNDING SOURCE: U.S. government Operation Warp Speed and National Institute of Allergy and Infectious Diseases.
Authors: Anil Gupta; Yaneicy Gonzalez-Rojas; Erick Juarez; Manuel Crespo Casal; Jaynier Moya; Diego R Falci; Elias Sarkis; Joel Solis; Hanzhe Zheng; Nicola Scott; Andrea L Cathcart; Christy M Hebner; Jennifer Sager; Erik Mogalian; Craig Tipple; Amanda Peppercorn; Elizabeth Alexander; Phillip S Pang; Almena Free; Cynthia Brinson; Melissa Aldinger; Adrienne E Shapiro Journal: N Engl J Med Date: 2021-10-27 Impact factor: 91.245
Authors: Dandan Shan; Joseph M Johnson; Syrena C Fernandes; Hannah Suib; Soyoon Hwang; Danica Wuelfing; Muriel Mendes; Marcella Holdridge; Elaine M Burke; Katie Beauregard; Ying Zhang; Megan Cleary; Samantha Xu; Xiao Yao; Purvish P Patel; Tatiana Plavina; David H Wilson; Lei Chang; Kim M Kaiser; Jacob Nattermann; Susanne V Schmidt; Eicke Latz; Kevin Hrusovsky; Dawn Mattoon; Andrew J Ball Journal: Nat Commun Date: 2021-03-26 Impact factor: 17.694
Authors: Peter C Taylor; Andrew C Adams; Matthew M Hufford; Inmaculada de la Torre; Kevin Winthrop; Robert L Gottlieb Journal: Nat Rev Immunol Date: 2021-04-19 Impact factor: 108.555
Authors: David M Weinreich; Sumathi Sivapalasingam; Thomas Norton; Shazia Ali; Haitao Gao; Rafia Bhore; Bret J Musser; Yuhwen Soo; Diana Rofail; Joseph Im; Christina Perry; Cynthia Pan; Romana Hosain; Adnan Mahmood; John D Davis; Kenneth C Turner; Andrea T Hooper; Jennifer D Hamilton; Alina Baum; Christos A Kyratsous; Yunji Kim; Amanda Cook; Wendy Kampman; Anita Kohli; Yessica Sachdeva; Ximena Graber; Bari Kowal; Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos Journal: N Engl J Med Date: 2020-12-17 Impact factor: 91.245
Authors: Rita E Chen; Emma S Winkler; James Brett Case; Ishmael D Aziati; Traci L Bricker; Astha Joshi; Tamarand L Darling; Baoling Ying; John M Errico; Swathi Shrihari; Laura A VanBlargan; Xuping Xie; Pavlo Gilchuk; Seth J Zost; Lindsay Droit; Zhuoming Liu; Spencer Stumpf; David Wang; Scott A Handley; W Blaine Stine; Pei-Yong Shi; Meredith E Davis-Gardner; Mehul S Suthar; Miguel Garcia Knight; Raul Andino; Charles Y Chiu; Ali H Ellebedy; Daved H Fremont; Sean P J Whelan; James E Crowe; Lisa Purcell; Davide Corti; Adrianus C M Boon; Michael S Diamond Journal: Nature Date: 2021-06-21 Impact factor: 49.962
Authors: Robert L Gottlieb; Ajay Nirula; Peter Chen; Joseph Boscia; Barry Heller; Jason Morris; Gregory Huhn; Jose Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Princy Kumar; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Michael Durante; Gerard Oakley; Andrew E Schade; Timothy R Holzer; Philip J Ebert; Richard E Higgs; Nicole L Kallewaard; Janelle Sabo; Dipak R Patel; Paul Klekotka; Lei Shen; Daniel M Skovronsky Journal: JAMA Date: 2021-02-16 Impact factor: 56.272
Authors: Jesse Fajnzylber; James Regan; Kendyll Coxen; Heather Corry; Colline Wong; Alexandra Rosenthal; Daniel Worrall; Francoise Giguel; Alicja Piechocka-Trocha; Caroline Atyeo; Stephanie Fischinger; Andrew Chan; Keith T Flaherty; Kathryn Hall; Michael Dougan; Edward T Ryan; Elizabeth Gillespie; Rida Chishti; Yijia Li; Nikolaus Jilg; Dusan Hanidziar; Rebecca M Baron; Lindsey Baden; Athe M Tsibris; Katrina A Armstrong; Daniel R Kuritzkes; Galit Alter; Bruce D Walker; Xu Yu; Jonathan Z Li Journal: Nat Commun Date: 2020-10-30 Impact factor: 14.919
Authors: Mamta K Jain; James A De Lemos; Darren K McGuire; Colby Ayers; Jennifer L Eitson; Claudia L Sanchez; Dena Kamel; Jessica A Meisner; Emilia V Thomas; Anita A Hegde; Satish Mocherla; Joslyn K Strebe; Xilong Li; Noelle S Williams; Chao Xing; Mahmoud S Ahmed; Ping Wang; Hesham A Sadek; John W Schoggins Journal: Front Pharmacol Date: 2022-09-30 Impact factor: 5.988
Authors: Brian P Epling; Joseph M Rocco; Kristin L Boswell; Elizabeth Laidlaw; Frances Galindo; Anela Kellogg; Sanchita Das; Allison Roder; Elodie Ghedin; Allie Kreitman; Robin L Dewar; Sophie E M Kelly; Heather Kalish; Tauseef Rehman; Jeroen Highbarger; Adam Rupert; Gregory Kocher; Michael R Holbrook; Andrea Lisco; Maura Manion; Richard A Koup; Irini Sereti Journal: medRxiv Date: 2022-06-17
Authors: Paul R Wratil; Niklas A Schmacke; Andreas Osterman; Matthias Klein; Oliver T Keppler; Tobias Weinberger; Jochen Rech; Burak Karakoc; Mira Zeilberger; Julius Steffen; Tonina T Mueller; Patricia M Spaeth; Marcel Stern; Manuel Albanese; Hella Thun; Julia Reinbold; Benedikt Sandmeyer; Philipp Kressirer; Béatrice Grabein; Peter Falkai; Kristina Adorjan; Veit Hornung; Lars Kaderali Journal: Infection Date: 2021-08-11 Impact factor: 7.455